The capsule Market is very hot, Hengrui, Qilu, Yangzi River Launch a "storm"

[pharmaceutical network industry trends] according to the data, the sales volume of capsules in the terminal pharmaceutical market of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) is showing a steady growth trend Among them, the sales volume of chemical medicine capsule increased from 45.351 billion yuan in 2013 to 82.802 billion yuan in 2018, and the sales volume of Chinese patent medicine capsule reached 74.078 billion yuan in 2018 Capsule refers to the preparation of drugs loaded into capsules according to the dosage In general, gelatin is the main raw material of the capsule Sometimes, in order to change its solubility or achieve enteric dissolution, methylcellulose, calcium alginate, denatured gelatin, PVA and other polymer materials are also used The capsule can cover the bad smell of the medicine and is easy to swallow; it can improve the stability and bioavailability of the medicine; it can also release the medicine at fixed time and make up for the shortage of other solid dosage forms, so it is widely used Among the top 20 chemical capsule brands of an organization, the sales of Novartis valsartan capsule, anstelai tacrolimus capsule, Shandong new era pharmaceutical's tegio capsule, Tianfang pharmaceutical's atorvastatin calcium capsule and stone medicine's EBP soft capsule exceeded 2 billion yuan Among the top 10 Chinese patent medicine capsule brands, the sales of Bailing Capsule of Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Naoxintong capsule of Shaanxi step Pharmaceutical Co., Ltd., Tongxinluo capsule of Shijiazhuang Yiling Pharmaceutical Co., Ltd., Suhuang cough relieving capsule of Beijing Haiyan Pharmaceutical Co., Ltd of Yangtze River all exceeded 1.5 billion yuan For example, as a kind of new drug, the soft capsule of EBP is mainly used in the treatment of acute ischemic stroke Green plant medicine, a major project of NSFC, has excellent safety single body structure and multiple pharmacological effects Comprehensive treatment of ischemic stroke can significantly reduce the neurological deficit after infarction and improve the living ability of patients According to data, among the top 20 brands of terminal peripheral vasodilators in China's public medical institutions in 2017, SMG's butylphthalide soft capsule ranked second with a market share of 22.52% Tongxinluo capsule, as the core product of Yiling pharmaceutical industry in Shijiazhuang, is a kind of medicine for the treatment of coronary heart disease, cerebral infarction and diabetic microangiopathy It is a national medical insurance category a variety and a national basic drug catalog variety According to Yiling pharmaceutical annual report, at present, Tongxinluo capsule, Lianhua Qingwen capsule, Shensong Yangxin capsule and other varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries, and Tongxinluo capsule has entered the national medical insurance catalog of Vietnam In 2018, the sales volume of Tongxinluo capsule in China's public medical institutions reached 1.966 billion yuan, a year-on-year increase of 6.01% In 2019, it is expected to break the 2 billion mark With the increasing sales volume of various enterprises in the capsule Market, the hot atmosphere of the capsule Market is also driven, which can be seen in the consistency evaluation Data shows that as of October 25, there are 25 products (51 product specifications) that have passed or deemed to pass the consistency evaluation, among which, Kelun, Yangzijiang, Hengrui and other enterprises have passed the evaluation, and 8 capsules have sales scale of more than 1 billion Among them, there are a lot of products that have been evaluated for systemic antibacterials, antineoplastic drugs and systemic antiviral drugs In addition, there are 34 capsules (involving acceptance No 98) that are under review for the supplementary application for conformity assessment, including 8 products from more than 3 enterprises under review Recently, with DRGs city pilot, accounting information inspection of 77 pharmaceutical companies, medical insurance catalog adjustment, auxiliary drug catalog and other policies swarming in, some insiders pointed out that the pharmaceutical industry has moved towards refined management and will pursue higher "cost performance" As far as the capsule Market is concerned, the pattern of domestic capsule enterprises in China is still small and scattered In addition, due to the competition of foreign enterprises and joint ventures, the development space of domestic enterprises is limited to a large extent How to share more market cakes under the premise of ensuring the quality of drugs is still a problem to be considered by Chinese pharmaceutical enterprises.